- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02105909
GWAS in a Small Group of Metabolically Healthy Obese White Adults
April 2, 2014 updated by: Doina Kulick, MD, University of Nevada, Las Vegas
Genome Wide Association Studies (GWAS) to Identify Candidate Obesity Susceptibility Genes in a Carefully Phenotyped, Metabolically Healthy Population of Obese White Adults
This is a GWAS pilot study that aims to identified possible candidate genes associate to obesity by exploring single nucleotide polymorphism (SNP) in a small group of obese , metabolically healthy white adults, matched with lean, white adults , metabolically healthy.
The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with obesity (as defined by BMI).
Study Overview
Detailed Description
Between 60%-70% of the risk of obesity appears to be heritable.
Unfortunately, the exact genes involved have been difficult to identify.
New technologies now exist to help researchers discover obesity susceptibility genes.
One of these technologies is the Affymetrix Genome-Wide Human SNP (single nucleotide polymorphism) Array 6.0 chips.
SNPs are individual base pair differences in genes of different individuals, and they are the main source of human genetic diversity.
The "chips" are thumbnail-size silicon surfaces that contain copies of hundreds of thousands of SNPs of the human genome (in this case around 900,000).
SNP chips allow researchers to screen thousands of genes in a single experiment and compare genes of subjects with a particular disease or condition with unaffected control subjects.
The investigators study utilizes SNP chips to compare the genetic profiles of obese subjects (N = 20, body mass index > 35 kg/m2) without common obesity-related co-morbidities such as diabetes mellitus or hypertension with well matched, lean controls (N = 20, body mass index 18-25 kg/m2).
This is a pilot study intended to explore the following: 1) possible associations between obesity and previously unidentified obesity susceptibility genes; 2) associations between known obesity genes and obesity risk in subjects without obesity-related metabolic co-morbidities; and 3) how well our genetic data conform to other studies in similar populations as a way of assessing if the investigators have identified a representative cohort of obese subjects.
Study Type
Interventional
Enrollment (Actual)
81
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- - Adults 40 year old or older
- Caucasian males or females
- BMI ≥ 35 kg/m² or history of BMI ≥ 35 kg/m², or BMi less than 25 kg/m2
- No current or past use of glucose lowering drugs
- No current or past medical history of diabetes mellitus
- No current or past medical history of established coronary artery disease (angina, myocardial infraction, abnormal cardiac stress test)
- No current or past medical history of or treatment for thyroid disorders
- No current or past use of lipid lowering drugs or diagnosis of a lipid disorder
- No current or past medical history of or treatment for hypertension
Subject's willingness to provide the study investigators with a copy of their medical records or give permission to the study investigators to access the following specific medical information:
- Fasting plasma glucose (less than 100 mg/dL/5.6 mmol/L)
- HDL-C cholesterol (more than 40 mg/dL /1.03 mmol/L)
- Total cholesterol (less than 239 mg/dL/ 6.18mmol/L)
- LDL cholesterol (less than 159 mg/dL/4.11 mmol/L)
Exclusion Criteria:
- - Known monogenic forms of obesity
- Polycystic ovary disease (in women)
- Malabsorptive or maldigestive syndromes (Celiac disease, Crohn's Disease, inflammatory bowel disease, etc.)
- Anorexia nervosa or bulimia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: obese subjects
DNA analysis
|
|
|
Placebo Comparator: lean subjects
DNA analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
number of SNPs associated with high BMI
Time Frame: baseline
|
Using GWAS to identify candidate genes associate with obesity (high BMI) in a carefully phenotyped white adults with obesity (as defined by BMI), metabolically healthy, matched with lean, white adults metabolically healthy.
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
March 26, 2014
First Submitted That Met QC Criteria
April 2, 2014
First Posted (Estimate)
April 7, 2014
Study Record Updates
Last Update Posted (Estimate)
April 7, 2014
Last Update Submitted That Met QC Criteria
April 2, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIH P20 RR-016464
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.